Samaritan's Phase II (Proof of Concept) Trial Shows Statistically Significant Positive Results With HIV Drug

		SAMARITAN PHARMACEUTICALS CORPORATE LOGO Samaritan Pharmaceuticals, in collaboration with Georgetown University, develops and strives to commercialize scientific breakthrough innovations for: Alzheimer's (AD) Drugs, to inhibit glucocorticoid-mediated neurotoxicity, an Animal Model to test AD drugs, an AD Diagnostic; a Breast Cancer Diagnostic; a peptide to bind Cholesterol and a late stage Phase II statistically significant HIV drug. Samaritan's patented pipeline is built on a, cholesterol-metabolism and glucocorticoid-biosynthesis, technology platform which is scientifically considered to be a successful therapeutic approach. (PRNewsFoto)[AS] LAS VEGAS, NV USA

LAS VEGAS, March 7 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals Inc. (OTC Bulletin Board: SPHC) and Samaritan Research Labs, Georgetown University, announced today that its HIV Phase Ib/IIa clinical trail data and analysis, conducted at, and led by Dr. Steven J. Brown, of the AIDS Research Alliance, Los Angeles, CA, has been provided to Samaritan. These clinical trial results will be submitted for publication to several medical journals. To prevent denial of publication for reasons of "pre-publication," and to preserve Samaritan's rights under our patent applications, the results will be kept confidential, pending publication. Phase II is a dose finding and "proof of concept" study conducted in a relatively small number of carefully selected HIV patients, plus a placebo- controlled group. In the Clinical trial, patients received several doses of the test drug (dose finding) and the resulting data allowed researchers and statisticians to make a quantitative assessment of drug effects. Samaritan believes our HIV drug has future potential and is developing its strategy for further development in Phase III. Statistically significant is a very important concept and plainly, is used anytime you like to know if "on average" something works or does not work. It works, if the results are statistically (that is, on average, everything else considered) significant. Click here: What is Statistically Significant? http://newton.dep.anl.gov/askasci/math99/math99052.htm About Samaritan Pharmaceuticals Samaritan Pharmaceuticals, in collaboration with Georgetown University, strives to commercialize breakthrough scientific innovation. Samaritan is primarily focused on the development of innovative therapies for Alzheimer's, Cancer, Cholesterol Reduction and HIV. The science that separates Samaritan's patented pipeline which is closest to commercialization includes: a completed HIV Phase II trial with positive significant data; an Animal (rat) model used to test Alzheimer's drugs; an Alzheimer's Predictor Diagnostic and Breast Cancer Tumor Aggressiveness Diagnostic; a Peptide that binds cholesterol; and a series of innovative neuroprotective compounds. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 26, 2002. The company undertakes no duty to update forward-looking statements. (Photo: http://www.newscom.com/cgi-bin/prnh/20030129/SPHCLOGO ) For further information please contact Gene Boyle, Business Development, GeneBoyle@aol.com , or Doug Bessert, Investor Relations, DougBessert@aol.com , both of Samaritan Pharmaceuticals, Inc., +1-702-735-7001, or fax, +1-702-737-7016. To receive future press releases and newsletters automatically, or for more information, visit our Web site at http://www.samaritanpharmaceuticals.com .